L-Tyrosine Ethylester

L-Tyrosine Ethylester

SCHEMBL3086510

CCOC(=O)[C@@H](N)Cc1ccc(O)cc1.OCl

nearest known ligand 0.57

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 1/20 0.57
TPH1 P17752 2/20 0.51
TAAR1 Q96RJ0 3/20 0.49
SLC6A2 P23975 1/20 0.49
ESR1 P03372 3/20 0.46
ESR2 Q92731 3/20 0.46
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA7 P43166 1/20 0.46
CA9 Q16790 1/20 0.46
CA14 Q9ULX7 1/20 0.46
HDAC8 Q9BY41 2/20 0.44
DPP4 P27487 1/20 0.44
ERAP2 Q6P179 1/20 0.42
LNPEP Q9UIQ6 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
L-Tyrosine Ethylester SCHEMBL242946 0.97 SLC7A5 (0.61) SLC7A5TPH1TAAR1SLC6A2ESR1
L-Tyrosine Ethylester SCHEMBL242947 0.97 SLC7A5 (0.61) SLC7A5TPH1TAAR1SLC6A2ESR1
L-Tyrosine Ethylester SCHEMBL9327871 0.97 SLC7A5 (0.61) SLC7A5TPH1TAAR1SLC6A2ESR1
L-Tyrosine Ethylester SCHEMBL595118 0.95 SLC7A5 (0.59) SLC7A5TPH1TAAR1SLC6A2ESR1
L-Tyrosine Ethylester SCHEMBL9331146 0.95 SLC7A5 (0.59) SLC7A5TPH1TAAR1SLC6A2ESR1
L-Tyrosine Ethylester SCHEMBL595119 0.95 SLC7A5 (0.59) SLC7A5TPH1TAAR1SLC6A2ESR1
L-Tyrosine Ethylester SCHEMBL1532619 0.94 SLC7A5 (0.57) SLC7A5TPH1TAAR1SLC6A2ESR1
L-Tyrosine Ethylester SCHEMBL27732314 0.94 SLC7A5 (0.57) SLC7A5TPH1TAAR1SLC6A2ESR1
L-Tyrosine Ethylester SCHEMBL30772131 0.94 SLC7A5 (0.57) SLC7A5TPH1TAAR1SLC6A2ESR1
L-Tyrosine Ethylester SCHEMBL27074524 0.94 SLC7A5 (0.57) SLC7A5TPH1TAAR1SLC6A2ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1905763-B1 N-ACYLIC AMINOACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, PHARMACOLOGICAL COMPOSITION AND THE USE IN THE FORM OF ANTI-ALLERGIC, ANTI-INFLAMMATORY AND HYPOLIPIDEMIC AGENTS NEBOLSIN VLADIMIR EVGENIEVICH (RU) 2019-05-08 EP disclosed
US-8940780-B2 N-acylic aminoacid derivatives, method for the production thereof, pharmacological composition and the use in the form anti-allergic, anti-inflammatory and hypolipidemic agents OTKRYTOE AKTSIONERNOE OBSCHESTVO OTECHESTVENNYE LEKARSTVA (RU) 2015-01-27 US disclosed
US-8318950-B2 N-acyl amino acid derivatives, a method for the preparation thereof, a pharmaceutical composition and use thereof as anti-allergic, anti-inflammatory and hypolipidemic agents Otkrytoe Aktsionernoe Obschestvo-Otechestvennye Lekarstva (RU) 2012-11-27 US disclosed
US-20100267962-A1 N-ACYLIC AMINOACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, PHARMACOLOGICAL COMPOSITION AND THE USE IN THE FORM ANTI-ALLERGIC, ANTI-INFLAMMATORY AND HYPOLIPIDEMIC AGENTS Nebolsin, Vladimir Evgenievich (RU) 2010-10-21 US disclosed
US-20080319040-A1 N-Acylic Aminoacid Derivatives, Method For The Production Thereof, Pharmacological Composition And The Use In The Form Anti-Allergic, Anti-Inflammatory And Hypolipidemic Agents OTKRYTOE AKTSIONERNOE OBSCHESTVO "OTECHESTVENNYE LEKARSTVA (RU) 2008-12-25 US disclosed
EP-1905763-A1 N-ACYLIC AMINOACID DERIVATIVES. METHOD FOR THE PRODUCTION THEREOF, PHARMACOLOGICAL COMPOSITION AND THE USE IN THE FORM OF ANTI-ALLERGIC, ANTI-INFLAMMATORY AND HYPOLIPIDEMIC AGENTS Nebolsin, Vladimir Evgenievich (RU) 2008-04-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267962-A1 N-ACYLIC AMINOACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, PHARMACOLOGICAL COMPOSITION AND THE USE IN THE FORM ANTI-ALLERGIC, ANTI-INFLAMMATORY AND HYPOLIPIDEMIC AGENTS HRH4, HRH2, AADAT SLC7A5 357/4885TPH1 479/4885TAAR1 602/4885
US-20080319040-A1 N-Acylic Aminoacid Derivatives, Method For The Production Thereof, Pharmacological Composition And The Use In The Form Anti-Allergic, Anti-Inflammatory And Hypolipidemic Agents HRH4, HRH2, AADAT SLC7A5 357/4885TPH1 479/4885TAAR1 602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.